Business Context and Reporting Period
Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2026
Business Overview: Travere is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its primary commercial product is FILSPARI (sparsentan), approved for Immunoglobulin A nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS). The company also markets Thiola/Thiola EC for cystinuria and is developing pegtibatinase for classical homocystinuria.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $127,199 | $81,732 |
| Net Product Sales | $124,492 | $75,861 |
| License & Collaboration Revenue | $2,707 | $5,871 |
| Net Loss | $(37,102) | $(41,226) |
| Net Loss Per Share (Basic & Diluted) | $(0.40) | $(0.47) |
| Cash and Cash Equivalents | $78,362 | $61,897 |
| Marketable Debt Securities | $186,314 | $229,761 |
| Total Convertible Debt | $312,079 | $311,724 |
| Stockholders' Equity | $98,728 | $114,828 |
Liquidity: As of March 31, 2026, the company held approximately $264.7 million in cash, cash equivalents, and marketable debt securities. Management believes this is sufficient to fund operations for more than 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $45.5 million (55.6%) year-over-year, driven primarily by a $49.3 million increase in FILSPARI sales ($105.2M vs. $55.9M). This growth follows the FDA's full approval of FILSPARI for IgAN in September 2024 and FSGS in April 2026.
- Operating Expenses: Total operating expenses rose by $39.7 million to $164.1 million.
- R&D: Increased by $10.2 million to $57.1 million, largely due to restarting enrollment in the Phase 3 HARMONY study for pegtibatinase.
- SG&A: Increased by $19.8 million to $80.3 million, reflecting commercial investments for FILSPARI launches.
- Royalty Expense: Increased by $12.4 million to $24.8 million, primarily due to elevated amortization of the Thiola intangible asset as it reached the end of its useful life.
- Accounting Presentation Change: The company reclassified $12.4 million of amortization expense from SG&A to a new "Royalty Expense" line item to better reflect costs associated with licensed products.
- Discontinued Operations: The company reported a $0.5 million loss from discontinued operations related to the sale of its bile acid portfolio to Mirum Pharmaceuticals.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- FILSPARI: The company is expanding its commercial organization to support the FSGS launch. FILSPARI is the first and only FDA-approved treatment for FSGS.
- Pegtibatinase: Enrollment in the pivotal Phase 3 HARMONY study was restarted in Q1 2026 after a voluntary pause in late 2024 to address manufacturing scale-up issues. Topline data is anticipated in the second half of 2027.
- Partnerships: Chugai Pharmaceutical acquired Renalys in Q4 2025, gaining exclusive rights to sparsentan in Japan, South Korea, and Taiwan. Travere received $10.2 million at closing and remains eligible for milestones and royalties.
Key Risks & Contingencies:
- Patent Litigation: In March 2026, a European patent (EP3222277) covering sparsentan for IgAN and FSGS was revoked following an appeal. The company expects to rely on data and marketing exclusivity in the EU instead.
- Regulatory & Pricing: Risks include potential changes in healthcare reimbursement, pricing regulations (e.g., Most-Favored Nation pricing), and the impact of generic competition on Thiola sales.
- Manufacturing: The company relies on third-party manufacturers. Past scale-up challenges with pegtibatinase highlight the risk of supply chain disruptions.
- Debt: The company has $316.3 million in 2.25% Convertible Senior Notes due 2029. Failure to generate sufficient cash flow could impact the ability to repay or refinance this debt.
Investor Verification Checklist
- FILSPARI Sales Trajectory: Verify the sustainability of the 88% year-over-year growth in FILSPARI sales and the impact of the new FSGS indication on future revenue.
- Pegtibatinase Timeline: Confirm the progress of the HARMONY study enrollment and the timeline for topline data (expected H2 2027) following the manufacturing restart.
- European Patent Status: Assess the financial impact of the revoked European patent (EP3222277) and the company's strategy to rely on data exclusivity in the EU.
- Thiola Royalty Amortization: Review the impact of the Thiola intangible asset reaching the end of its useful life on future royalty expenses and margins.
- Liquidity Runway: Monitor cash burn rates relative to the $264.7 million in liquid assets to ensure sufficiency for the 2029 Notes maturity and ongoing R&D.